---
title: "阿斯利康的高血壓藥物獲得美國批准"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286724028.md"
description: "阿斯利康已獲得美國對其高血壓藥物 Baxfendy（前稱 baxdrostat）的批准，該藥物通過靶向醛固酮來降低血壓。公司預計年峯值銷售額將超過 50 億美元。此項批准增強了阿斯利康在心血管和腎臟治療領域的產品組合，此前其糖尿病藥物 Farxiga 的專利已到期。FDA 的決定基於成功的晚期試驗，顯示該藥物在無法控制的高血壓患者中有效。阿斯利康計劃到 2030 年推出 20 種新藥，目標是實現 800 億美元的收入"
datetime: "2026-05-18T06:30:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286724028.md)
  - [en](https://longbridge.com/en/news/286724028.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286724028.md)
---

# 阿斯利康的高血壓藥物獲得美國批准

By Adria Calatayud

AstraZeneca said it received U.S. approval for a new hypertension treatment, getting the green light to launch a drug the U.K. pharmaceutical company expects to generate multibillion-dollar annual sales at its peak.

The drug, known until now as baxdrostat, will be marketed under the brand name Baxfendy, the company said Monday. The approval expands AstraZeneca's cardiovascular, renal and metabolism portfolio shortly after diabetes drug Farxiga--its biggest product in that therapeutic area and the bestselling medicine in the company's history--went off patent in the U.S.

AstraZeneca said that Baxfendy treats hypertension in a new way by targeting aldosterone, a hormone that raises blood pressure.

Ruud Dobber, executive vice president of AstraZeneca's biopharmaceuticals business, said the approval brings a new treatment to a disease that has had little therapeutic progress for the past two decades.

The U.S. Food and Drug Administration approved the drug as a treatment of hypertension in adults in combination with other medications, the company said. The decision was based on results of a late-stage clinical trial that showed the drug reduced blood pressure in patients with uncontrolled hypertension who were on two or more medications, it added.

Executives at AstraZeneca previously said revenue from the product could top $5 billion at its peak. The drug is one of the 20 new medicines the company aims to launch by the end of the decade, as part of its goal to achieve revenue of $80 billion by 2030.

AstraZeneca, which gained control of Baxfendy through its acquisition of CinCor Pharma in 2023, is looking to expand its portfolio in cardiovascular, renal and metabolism diseases with new products such as its experimental drug, elecoglipron, for weight loss.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

May 18, 2026 02:20 ET (06:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### 相關股票

- [AZN.US](https://longbridge.com/zh-HK/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/zh-HK/quote/AZN.UK.md)
- [CINC.US](https://longbridge.com/zh-HK/quote/CINC.US.md)

## 相關資訊與研究

- [阿斯利康高血壓藥物獲美國批准](https://longbridge.com/zh-HK/news/286741013.md)
- [阿斯利康降壓藥獲美國批准](https://longbridge.com/zh-HK/news/286720674.md)
- [百濟神州創新藥獲美加速批准上市，該國首款治復發或難治套細胞淋巴瘤](https://longbridge.com/zh-HK/news/286333558.md)
- [維立志博抗癌雙抗藥獲批內地三期臨牀，最快第三季申上市](https://longbridge.com/zh-HK/news/286831504.md)
- [已逾 8 千人服用！血管炎藥在日本造成 20 死 藥商籲暫停給藥](https://longbridge.com/zh-HK/news/286640523.md)